Trial of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU; NSC-79037) in advanced bronchogenic carcinoma 1,2,3.
A total of 103 patients with lung cancer was treated with CCNU 130 mg/m2 orally every 6 weeks; 65 patients survived at least 6 weeks. Partial responses occurred in 7 patients. Leukopenia, thrombocytopenia, and nausea were frequent toxic effects. CCNU has slight efficacy in advanced lung cancer. No increase in survival was attributed to therapy.